Sanjay Sethi MD

Sanjay Sethi

Sanjay Sethi
MD

Professor and Chief, Pulmonary, Critical Care and Sleep Medicine; Assistant Vice President for Health Sciences

Department of Medicine

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Pulmonary & Critical Care Medicine

Contact Information
Clinical and Translational Research Center
875 Ellicott St.
Room 6045A
Buffalo, New York 14215
Phone: 7168884864
ssethi@buffalo.edu


Patient Care

This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.

View this physician on UBMD


Professional Summary:

As chief of the division of pulmonary, critical care and sleep medicine, I oversee clinical, teaching, research and administrative tasks related to the evaluation and treatment of adult patients with lung diseases and sleep disorders as well as critically ill patients. My outpatient practice is at UBMD Internal Medicine clinics at Conventus in the Downtown Medical Campus and at Youngs road in Amherst. My inpatient practice is primarily located at the VA Medical Center (VA) in Buffalo. Members of my division provide care at sites throughout Buffalo, including the UBMD clinics, UBMD Sleep Center and other UB-affiliated hospitals.

I also conduct research on one of the most common lung diseases: chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, and lung infections such as bronchitis and pneumonia. Interestingly, patients with COPD become more prone to lung infection, and understanding why and how this happens is my main research interest. In addition to bench research in this field, I am also working to develop better ways to prevent and treat these infections by leading and participating in several clinical research studies in this field that are open to both veterans and the general public. I lead a multidisciplinary research team based at UB and the VA that includes pulmonary and infectious disease physicians, post-doctoral scientists, nurse coordinators and research assistants. Through mentored research programs, our laboratories train undergraduate and graduate students, residents and fellows.

I am active in several professional organizations and have served as a consultant on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.

Education and Training:

  • Certificate, Executive Development in Healthcare Management Certificate Program, University at Buffalo (2015)
  • MBBS, Maulana Azad Medical College (1994)
  • Fellowship, Pulmonary and Critical Care, University at Buffalo (1993)
  • Residency, Cook County Hospital (1990)
  • Internship, Cook County Hospital (1988)
  • Other, MBBS, Maulana Azad Medical College (1984)
  • AISSC, St. Xavier's High School (1979)

Employment:

  • Deputy Director, UB Clinical & Translational Science Institute, University at Buffalo (2020-present)
  • Director, Clinical Research Office, University at Buffalo (2016-present)
  • Assistant Vice President of Health Sciences, University at Buffalo (2015-present)
  • Staff Physician - Division of Pulmonary & Critical Care and Sleep Medicine Medicine, Western New York, VA HealthCare System (2010-present)
  • Chief, Division of Pulmonary, Critical Care & Sleep Medicine, University at Buffalo (2007-present)
  • Staff Physician, VA Western New York Healthcare System (2010-present)
  • Chief, Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo (2007-present)
  • Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2006-present)
  • Medical Director, Clinical Research Office, University at Buffalo (2015–2016)
  • Vice Chair for Research, Department of Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2012–2015)
  • Section Chief, VA Western NY Healthcare System (2007–2010)
  • Staff Physician, VA Western New York Healthcare System (1993–2007)
  • Associate Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2001–2006)
  • Assistant Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (1996–2001)
  • Buswell Research Fellow, University at Buffalo (1993–1996)
  • Research Assistant Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (1993–1996)
  • Clinical Instructor, University at Buffalo (1990–1993)
  • Fellow, University at Buffalo (1990–1993)
  • Private Practice, Self Employed, Delhi, India, General Medicine (1985–1987)
See all (9 more)

Awards and Honors:

  • SUNY Chancellor Award for Excellence in Scholarship & Creative Activities (2020)
  • Stockton Kimball Award (2019)
  • Expertscape Recognition (2013)
  • Fellow of the American College of Physicians (2009)
  • Honorable mention for performance as intern and resident at Cook County Hospital
  • Merit Scholarships awarded by Delhi University based on performance in the
  • Who‘s Who in Science and Engineering
  • Distinguished Scientist and Sustained Achievement Award, University at Buffalo

Research Expertise:

  • Bacterial infection in COPD
  • Epidemiology and clinical implications of antimicrobial resistance
  • Innate lung defense in COPD
  • New therapeutics in COPD

Research Centers:

  • Clinical and Translational Research Center (CTRC)

UB 2020 Strategic Strengths:

  • Health and Wellness Across the Lifespan

Grants and Sponsored Research:

  • January 2016–January 2019
    Clinical Translational Science Award (CTSA)
    National Institutes of Health
    Role: Co-Investigator
    $16,000,000
  • September 2012–September 2014
    A Randomized, Double-blind, Placebo-controlled Study to evaluate the safety of long term use of Perforomist (formoterol fumarate) inhalation solution in subjects with COPD. Direct costs - $6,000/subject.
    Dey
    Role: Principal Investigator
  • September 2010–August 2014
    Bacterial Infection in COPD
    VA Merit Review
    Role: Principal Investigator
    $550,000
  • August 2012–July 2014
    A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 (IL1RA) in Chronic Obstructive Pulmonary Disease. Direct costs -$27,000/subject.
    Medimmune
    Role: Principal Investigator
    $27,000
  • September 2010–August 2013
    Sulforaphane Treatment in COPD as a Novel Interventional Strategy to Enhance Innate Immunity
    National Heart, Lung and Blood Institute
    Role: Principal Investigator
    $350,000
  • September 2010–August 2013
    Enhancing Nrf2 by Sulforaphane Treatment in COPD as a Novel Interventional Strategy
    National Heart, Lung and Blood Institute
    Role: Principal Investigator
    $360,000
  • July 2010–June 2013
    Investigating the presence and role of biofilms in COPD and their potential contribution to exacerbations of COPD.
    Astra Zeneca
    Role: Principal Investigator
    $400,000
  • April 2011–April 2013
    Defining the Mechanisms of the Increased Risk of Community Acquired Pneumonia in COPD Patients Treated with Inhaled Corticosteroids
    Astra Zeneca
    Role: Co-Investigator
    $218,880
  • December 2010–December 2012
    Defining a Role for Inhaled Calcium in Augmenting the Alveolar Macrophage Innate Immune Response to Infection in COPD
    Pulmatrix
    Role: Co-Investigator
    $115,200
  • July 2009–June 2012
    A six month Randomized Controlled Trial of Lung Flute in Patients with COPD
    Medical Acoustics, Inc
    Role: Principal Investigator
    $210,000
  • June 2010–September 2010
    Determination of in vitro effects of iCALM on COPD sputum.
    Pulmatrix
    Role: Principal Investigator
    $35,000
  • March 2005–August 2010
    Bacterial infection in COPD.
    VA Merit Review
    Role: Principal Investigator
  • July 2010–June 2010
    A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID in Comparison to Salmeterol 50mcg BID on the Rate of Exacerbations of COPD Following Hospitalization.
    Glaxo Smith Kline
    Role: Co-Investigator
  • December 2008–April 2010
    Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to prevent Acute Exacerbations in High Risk COPD Patients.
    MPEX Pharmaceuticals
    Role: Principal Investigator
  • July 2007–April 2010
    A Randomized, Double-Blind, Placebo Controlled, Exploratory Study to Assess the Safety and Efficacy of Multiple Doses of ACZ885 in COPD Patients.
    Novartis
    Role: Principal Investigator
  • August 2003–July 2009
    Randomized double blind trial of the effect of Advair on bacterial colonization.
    Glaxo Smith Kline
    Role: Co-Investigator
    $96,000
  • January 2008–June 2009
    A Proof of Principle Randomized Controlled 8 Week Study of the Safety and Efficacy of the Lung Flute in Adults with Chronic Obstructive Pulmonary Disease a FDA 510(k) Equivalency Study.
    Role: Principal Investigator
    $144,000
  • June 2007–June 2009
    A Phase IIIB twelve month, double blind, double dummy, randomized, parallel group, multi-center exacerbation study of Symbicort PMDI and 80/4.5 compared to formeterol turbohaler in COPD subjects.
    Astra Zeneca Pharmaceuticals
    Role: Principal Investigator
  • June 2008–September 2008
    A Phase 1, Multicenter, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Solution for Inhalation Administered for 5 days to Chronic Bronchitis Patients.
    MPEX Pharmaceuticals
    Role: Principal Investigator
  • June 2007–June 2008
    A Randomized, Double-Blind, Double-Dummy, Parallel Group Trial Comparing 12 Weeks Treatment with Tiotropium Inhalation Capsules 18mcg Via the HandiHaler Once Daily to Combivent Inhalation
    Boehringer Ingelheim,
    Role: Principal Investigator
  • June 2005–June 2008
    A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort pMDI 2 X 160/4.5 ug
    Astra-Zeneca
    Role: Principal Investigator
  • May 2007–December 2007
    Genotyping Analysis of Streptococcus pneumoniae strains isolated from the PERSPECTIVE study.
    Sanofi-Aventis Pharmaceuticals
    Role: Co-Principal Investigator
    $60,000
  • June 2006–June 2007
    A Prospective Observational Study for the Psychometric Validation of a Patient Reported Questionnaire in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
    Glaxo Smith Kline
    Role: Principal Investigator
  • August 2004–June 2007
    A double blind, randomized, placebo controlled study to investigate intermittent pulse therapy of Moxifloxacin as a prevention of acute exacerbation of chronic bronchitis.
    Bayer Pharmaceuticals
    Role: Principal Investigator
  • January 2004–March 2006
    Comparison of sputum induction with the Lung Flute with hypertonic saline and sham flute in COPD.
    Role: Principal Investigator
  • September 2000–August 2005
    Haemophilus antigen regulation of inflammation in COPD.
    National Heart, Lung & Blood Institute
    Role: Principal Investigator
    $700,000
  • June 2004–May 2005
    A phase 2 placebo controlled randomized double blind study of the efficacy and safety of Tofimilast dry powder inhalation in COPD.
    Pfizer
    Role: Principal Investigator
  • May 2004–September 2004
    Comparison of sputum induction with the Lung Flute with hypertonic saline and sham flute in healthy adults.
    Medical Acoustics
    Role: Principal Investigator
  • October 2000–September 2004
    Enhancing clinical research at the Buffalo VA.
    VA Research Enhancement
    Role: Co-Principal Investigator
  • October 2000–September 2004
    Quality of Life assessment in acute exacerbations of COPD.
    VA Research Enhancement
    Role: Principal Investigator
  • November 2002–September 2003
    A trial of Tiotropium versus placebo assessing proportion of patients experiencing exacerbation and proportion of patients hospitalized with exacerbation of COPD.
    Role: Principal Investigator
  • May 2002–April 2003
    Comparison of sputum induction with the Lung Flute with hypertonic saline in patients with COPD.
    Medical Acoustics
    Role: Principal Investigator
    $15,000
  • May 2002–April 2003
    Sputum induction with the Lung Flute in healthy subjects.
    Medical Acoustics
    Role: Principal Investigator
  • July 2001–April 2003
    A phase 3 trial of comparative efficacy of Clarithromycin extended release and immediate release tablets in acute exacerbations of chronic bronchitis.
    Boehringer Ingelheim Pharmaceuticals
    Role: Principal Investigator
  • October 2000–March 2003
    Effect of amoxicillin/clavulanate on chronic lower respiratory tract inflammation in patients with chronic bronchitis.
    SmithKline Beecham Pharmaceuticals
    Role: Principal Investigator
  • October 1998–September 2001
    Quality of life in COPD: Impact of steroids and chronic inflammation.
    VA Research Enhancement
    Role: Principal Investigator
  • October 1998–September 2001
    Outer membrane protein B1 of Moraxella catarrhalis.
    VA Merit Review
    Role: Principal Investigator
    $161,400
  • October 1996–September 2000
    Bacterial infection in COPD.
    VA Merit Review
    Role: Co-Investigator
  • July 2000–June 2000
    Comparative study of Gemifloxacin vs Levofloxacin in acute exacerbations of chronic bronchitis.
    Glaxo Smith Kline
    Role: Principal Investigator
  • July 1999–June 2000
    Comparative study of Clarithromycin extended release vs Augmentin in acute exacerbations of chronic bronchitis
    Abbott
    Role: Principal Investigator
  • July 1999–June 2000
    Comparative study of Gemifloxacin vs Clarithromycin in acute exacerbations of chronic bronchitis.
    Glaxo Smith Kline
    Role: Principal Investigator
  • July 1998–May 1999
    Mucosal immunity to Moraxella catarrhalis.
    VA Research Enhancement
    Role: Principal Investigator
  • July 1995–July 1997
    Systemic corticosteroids in COPD exacerbations.
    VA Cooperative Studies,
    Role: Principal Investigator
    $20,000
  • October 1993–September 1996
    Bacterial infection in COPD.
    VA Merit Review
    Role: Co-Investigator
  • July 1993–June 1996
    Immune response to Moraxella catarrhalis in bronchiectasis.
    Buswell research fellowship
    Role: Principal Investigator
See all (35 more)

Patents:

  • Gene encoding outer membrane protein B1 of Moraxella catarrhalis.
  • Method for detecting bacterial exacerbations of chronic obstructive pulmona
  • Vaccine for Nontypeable H. influenzae infection.

Journal Articles:

See all (185 more)

Books and Book Chapters:

  • Berim I., Sethi S. (2012) Community acquired pneumonia. In: Community acquired pneumonia (book chapter).
  • Parameswaran GI, Sethi S. (2012) Viral Pneumonia. In: Viral Pneumonia (book chapter).
  • Sethi S. (2011) Netter’s Infectious Diseases. In: Fungal infections.
  • Sethi S. (2011) Netter’s Infectious Diseases. In: Acute Exacerbations of COPD.
  • Sethi S ;Desai H. (2010) In: Humoral and Pulmonary Defenses against Respiratory Infections in COPD Patients.
  • Sethi S ; Desai H. (2010) Respiratory Infections. In: Exacerbations of Chronic Obstructive Pulmonary Disease. Informa Inc
  • Sethi S. (2009) Therapeutic Strategies in Acute Exacerbations of COPD. In: Infectious etiologies in acute exacerbations of COPD. Book chapter in Therapeutic Strategies in Acute Exacerbations of COPD. Clinical publishing
  • Sethi S. (2008) Clinical management of chronic obstructive pulmonary disease. In: Treating and preventing Infections, book chapter in Clinical Management of Chronic Obstructive Pulmonary Disease. Informa Healthcare
  • Sethi S. (2008) Chronic Obstructive Lung Diseases 2nd Edition. In: Bacterial infection, book chapter in Chronic Obstructive Lung Diseases 2nd Edition. B.C. Decker Inc.,
  • Sethi S. (2008) Asthma and COPD. 2nd Edition. In: Antibiotics. Book Chapter in Asthma and COPD, 2nd Edition. Academic Press
  • Sethi S;Desai H. (2008) Acute Exacerbations of COPD. In: Do airway bacteria cause COPD exacerbations? Book Chapter in Acute Exacerbations of COPD. Informa Inc.
  • Sethi S, Blasi F. (2007) Clinical Challenges in COPD. In: Antibiotics allergy in a COPD patient with frequent bacterial exacerbations. Book Chapter in Clinical Challenges in COPD. Clinical Publishing
  • Sethi S. (2007) Chronic Obstructive Pulmonary Disease. In: Bacteria, Book chapter in Chronic Obstructive Pulmonary Disease. Blackwell Publishing
  • Sethi,S./author of chapter Editors: Voelkel, N.F. & MacNee, W. Publisher: B.C. Decker, Inc. (2001) In: Bacterial Infection, book chapter in Chronic Obstructive Lung Diseases.
See all (4 more)

Abstracts:

  • Castner J, Jungquist C, Mammen MJ, Pender J J, Licata O, Wilding G, Sethi S. (2018) Developing Multivariable Prediction Models of Asthma Control Components Using Fitness Tracker Sleep Patterns in Women. (May)
  • Mammen MJ, Buck M, Sun Y, Waldron N, Valiyaparambil S, Wrona C, Sethi S. (2018) Distinct Airway Microbiome Patterns Associated with Lung Cancer Development in a COPD Cohort. (May)
  • Mammen MJ, Tsompana M, Buck M, Biswal S, Criner GJ, Sethi S. (2017) Effect Of Sulforaphane Treatment On The Airway Microbiome In COPD. (May)
  • Kraskovsky V., Smith M., Sethi S, Provost K. (2016) Differences in COPD blood monocyte populations do not affect maturation to mature tissue macrophage by ex-vivo GMCSF. (May)
  • Sethi S, Kim J., Wrona C., Eberhardt E., Grove L., Murphy TF. (2015) Distinguishing Infecting (New) from Colonizing (Pre-Existing) Nontypeable Haemophilus Influenzae and Moraxella Catarrhalis Strains at Exacerbation of COPD by Molecular and Immunological Assay. (May)
  • Rennard S.I., Martinez F.J., Sethi S, Zhu H., Haberman R., Zovko E. (2015) Effects of Roflumilast in COPD Patients Receiving ICS/LABA Fixed-Dose Combination: Rationale and Design of a Prospective Randomized Controlled Trial. (May)
  • Calverley P.M., Sethi S, Dawson M., Ward C., Newbold P., Van Der Merwe R. (2015) A Phase 2 Study of MEDI8968, an Anti-Interleukin-1 Receptor I (IL-1RI) Monoclonal Antibody, in Adults with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease. (May)
  • Majumdar S., Wrona C., Sethi S. (2015) Host and Bacterial Proteases Contribute to the Proteolysis of Sputum Secretory IgA (sIgA) in COPD Exacerbations. (May)
  • Roos A., Nikota J.K., Bjermer L.H., Bauer C.M., Stevenson C.S., Sethi S, Erjefalt J.S., Stampfli M.R. (2015) IL-17A is Increased in Advanced COPD and During AECOPD. (May)
  • Mohan A., Dhillon SS, Herschberger P., Mahoney MC, Reid M., Sethi S. (2015) Marked Seasonal Variability Can Affect Vitamin D Deficiency Prevalance in Veterans with Chronic Obstructive Pulmonary Disease. (May)
  • Majumdar S., Wrona C., Sethi S. (2015) Proteolysis of Sputum Secretory IgA in Bacterial Exacerbations of COPD. (May)
  • Provost K, Smith M., Mohan A., Sahib K., Conway S., Sethi S. (2015) The Epidemiologic Burden of Streptococcus Pneumoniae Colonization and Infection in Chronic Obstructive Pulmonary Disease. (May)
  • Ray AD, Dhillon SS, Mohan A., Mahoney MC, Hutson AD, Hershberger P., Sethi S, Reid M. (2015) Vitamin D is Inversely Associated with Body Mass Index and Smoking Status in COPD. (May)
  • Burns K., Wrona C., Grove L., Eberhardt E., Sethi S. (2014) New Strain Acquisition Of Citrobacter spp And Stenotrophomonas spp In COPD Is Not Associated With Exacerbations. (May)
  • Mohan A., Eberhardt E., Grove L., Murphy TF, Parameswaran GI, Sethi S. (2014) Clinical Features Of Exacerbations Of Chronic Obstructive Pulmonary Disease Are Related To Sputum Microbiology. (May)
  • Rangelov K., Butkowski O., Wrona C., Woodruff P.G., Dransfield M.T., Sethi S. (2014) Chronic Azithromycin Use In COPD Is Associated With Reduction In Serum Antibodies To Nontypeable Haemophilus Influenzae. (May)
  • Huang Y.J., Sethi S, Murphy TF, Nariya S., Boushey H.A., Lynch S.V. (2014) Bacterial Airway Microbiome Dynamics In Exacerbations Of Chronic Obstructive Pulmonary Disease. (May)
  • Bowman S., Yin J., Grove L., Wrona C., Sethi S. (2013) COPD exacerbation associated strains of Nontypeable Haemophilus influenzae form greater flow cell biofilms than colonizing strains. (May)
  • Bowman S., Pang B., Swords W., Anderson P., Grove L., Wrona C., Sethi S. (2013) Molecular and Microscopic detection of Nontypeable Haemophilus influenzae and Pseudomonas aeruginosa Biofilms in COPD sputa. (May)
  • Parameswaran GI, Sethi S, Willet A., Lesse AJ. (2013) Methicillin-Resistant Staphylococcus aureus (MRSA) in COPD. (May)
  • Provost K, Smith M., Arold S.P., Hava D.L., Sethi S. (2013) Extracellular Calcium augments the innate immune response of monocyte derived macrophages to bacterial challenge in patients with COPD by augmenting pattern recognition receptor expression. (May)
  • Parameswaran GI, Sethi S, Willet A., Wrona C. (2013) Nontypeable Haemophilus influenzae induces excessive TLR2 driven NF-kb activation in COPD airway epithelial cells. (May)
  • Mammen MJ, Tu C., Qu S., Sethi S. (2013) Pathway analysis of bronchoalveolar lavage fluid proteome of individuals with COPD compared to healthy controls. (May)
  • Mammen MJ, Tu, Chengjian, Qu, Jun, Sethi S. (2013) Pathway Analysis Of Bronchoalveolar Lavage Fluid Proteome Of Individuals With COPD Compared To Healthy Controls. (May) A1109
  • Wilson A., Anzueto A., Miravitlles M., Arvis P., Haverstock D., Trajanovic M., Sethi S. (2012) Prognostic factors for short and long term outcomes of outpatient exacerbations in moderate-to-severe COPD. (Sep)
  • Houle C., Murray L., Stolar M., Hsieh R., Jones P.W., Monz B., Ramachandran S., Goldman M., Sethi S, Leidy N.K. (2012) Quantifying The Severity Of Respiratory Symptoms Of Chronic Obstructive Pulmonary Disease (COPD): Performance Properties Of The EXAcerbations Of Chronic Pulmonary Disease Tool - Respiratory Symptoms (E-RS) In 3 Randomized Controlled Trials. (May)
  • Berim I., Wrona C., Eberhardt E., Berenson CS, Palaniyar N., Sethi S. (2012) Relationship Of Bronchoalveolar Lavage Levels Of Surfactant Proteins A And D In COPD To Exacerbation Susceptibility, Severity Of Airflow Obstruction And Current Tobacco Smoke Exposure. (May)
  • Houle C., Murray L., Stolar M., Hsieh R., Jones P., Sethi S, Ramachandran S., Goldman M., Leidy N.K. (2012) Reliability And Validity Of EXAcerbations Of Chronic Pulmonary Disease Tool (EXACT) Scores In 3 Clinical Trials. (May)
  • Provost K, Smith M., Kaushal G., Arold S.P., Hava D.L., Sethi S. (2012) Extracellular Calcium During Bacterial Challenge Augments The Innate Immune Response Of Monocyte Derived Macrophages. (May)
  • Sethi S, Rennard S.I., Miravitlles M., Martinez F.J., Donohue J.F., Anzueto A., Grossman R., Loutit J., Dudley M.N. (2012) A Phase 2 Study To Evaluate The Safety, Tolerability And Efficacy Of Levofloxacin Inhalation Solution (MP-376) Administered For 5 Days Every 28 Days To Prevent Acute Exacerbations In High Risk COPD Patients. (May)
  • Mammen MJ, Qu J, Sethi S. (2012) Comprehensive Proteomic Profiling Of Bronchoalveolar Lavage Fluid Of Individuals With COPD Compared To Healthy Controls. (May) A3747
  • Nag N., Bowman S.M., Grove L., Yin J., Sethi S. (2012) Static Biofilm Formation Is Not Associated With Longer Duration Of Carriage Of Pseudomonas Aeruginosa Strains In COPD. (May)
  • Jamil M.O., Yin J., Nag N., Eberhardt E., Grove L., Parameswaran GI, Murphy TF, Sethi S. (2012) Acquistion Of Pseudomonas Aeruginosa Is Associated With Adverse Clinical Outcomes In COPD. (May)
  • Mammen MJ, Qu J, Sethi S. (2012) Comprehensive Proteomic Profiling Of Bronchoalveolar Lavage Fluid Of Individuals With COPD Compared To Healthy Controls. (May)
  • Biswal S., Harvey C., Thimmulappa R.K., Sethi S, Brown R., Feller-Kopman D.J., Wise R.A. (2012) Enhancing Nrf2 By Sulforaphane Improve Bacterial Phagocytosis By COPD Macrophages And Reduces Bacterial Exacerbations In Cigarette Smoke-Exposed Mice. (May)
  • Sethi S, Wrona C., Eberhardt E., Grove L., Parameswaran GI, Murphy TF. (2012) Distinguishing Infecting (New) From Colonizing (Pre-Existing) Nontypeable Haemophilus Influenzae Strains At Exacerbation Of COPD By Molecular And Immunological Assays. (May)
  • Parameswaran GI, Sethi S, Murphy TF. (2012) Transcriptional And Cytokine Responses Of Airway Epithelial Cells To Infection In COPD. (May)
  • Parameswaran GI, Murphy TF, Yin J., Grove L., Eberhardt E., Berenson CS, Sethi S. (2012) Species Specific Susceptibility To Bacterial Colonization And Exacerbation In COPD. (May)
  • Sethi S, Anzueto A., Miravitlles M., Arvis P., Alder J., Haverstock D., Trajanovic M., Wilson R. (2011) Moxifloxacin (MXF) vs. Amoxicillin/Clavulanic Acid (AMC) In Acute Exacerbations of COPD (AECOPD): Bacteriologic Results of the MAESTRAL Study. (Sep)
  • Wilson R., Anzueto A., Miravitlles M., Arvis P., Alder J., Haverstock D., Trajanovic M., Sethi S. (2011) Moxifloxacin (MXF) vs. amoxicillin/clavulanic acid (AMC) in acute exacerbations of COPD (AECOPD): Results of a large clinical trial with a novel endpoint. (Sep)
  • Wilson R., Sethi S, Anzueto A., Miravitlles M., Haverstock D., Trajanovic M., Arvis P. (2011) Maestral (Moxifloxacin In AECB Superiority Trial) Study Protocol: Use Of A Novel 8-Week Post-Therapy Endpoint. (May)
  • Berim I.G., Lesse AJ, Eberhardt E., Grove L.J., Wrona C., Murphy TF, Sethi S. (2011) New Strain Acquisition Of Staphylococcus Aureus In Chronic Obstructive Pulmonary Disease Is Not Associated With Exacerbations. (May)
  • Sexton C.C., Leidy N.K., Notte S.M., Jones P., Monz B.U., Nelsen L., Ramachandran S., Sethi S. (2011) Quantifying The Severity Of Respiratory Symptoms Of Chronic Obstructive Pulmonary Disease (COPD): Reliability And Validity Of A Patient Diary. (May)
  • Parameswaran GI, Sethi S, Murphy TF. (2011) Effects Of Bacterial Infection On Airway Antimicrobial Peptides And Proteins In Chronic Obstructive Pulmonary Disease. (May)
  • Huang Y.J., Sethi S, Wrona C., Boushey H,A,, Lynch S. (2011) Airway Bacterial Microbiota Dynamics During COPD Exacerbations. (May)
  • Desai H.D., Grant B.J.B., Eschberger K., Agrawal A., Murphy TF, Sethi S. (2011) Bacterial Colonization Of The Lower Respiratory Tract Increases Daily Symptoms In Patients With Chronic Obstructive Pulmonary Disease. (May)
  • Sethi S, Berenson CS, Clare R.L., Eberhardt E., Wrona C. (2011) Association Of Impaired Innate Immune Responses Of COPD Alveolar Macrophages With Toll-Like Receptor Polymorphisms. (May)
  • Sansgiry S.S., Joish V.N., Boklage S., Goyal R., Seal B., Sethi S. (2010) Pseudomonas aeruginosa related burden on Cystic Fibrosis patients: Comparing healthcare costs and resource utilization across age groups. (Nov)
  • Sansgiry S.S., Joish V.N., Boklage S., Goyal R., Seal B., Sethi S. (2010) Pseudomonas aeruginosa related economic burden stratified by comorbidity in Cystic Fibrosis patients. (Nov)
  • Sethi S. (2010) Impact of Pseudomonas aeruginosa infection on direct medical costs in Cystic Fibrosis. (Oct)
  • Sethi S;Harvey CJ, Thimmulappa RK,Yarmus L, Feller-Kopman D, Wise R and S Biswal. (2010) Nrf2-dependent immunomodulation by sulforaphane improves bacterial phagocytosis in COPD macrophages and inhibits bacterial burden and inflammation in cigarette smoke-exposed mice. (May)
  • Sethi S;Desai H, Wrona C, Murphy TF,. (2010) Mechanisms of decline in serum bactericidal activity for Nontypeable Haemophilus influenzae (NTHI) in COPD patients chronically colonized with NTHI. (May)
  • Sethi S;Jowdy P, Desai H. (2010) Proteolysis of Sputum Immunoglobulin A (IgA) in Exacerbations of Chronic Obstructive Pulmonary Disease. Poster Discussion session. (May)
  • Sethi S;Desai H, Eschberger K, Agrawal A, Grant BGB, Murphy TF. (2010) Environmental factors and daily symptoms in patients with Chronic Obstructive Pulmonary Disease. (May)
  • Sethi S;Eberhardt E, Wrona C, Grove LJ, Clare R, Berenson CS. (2010) Bacterial pathogen induction of interleukin-8 (IL-8) and adherence to primary bronchial epithelial cells obtained from patients with COPD. (May)
  • Sethi S;Sigua N, Rajashekhar G, Fehrenbach H, Kamocki K, Adamowicz J, Garrison J, Rush NI, Voswinckel R, Twigg III HL,Clauss M, I. Petrache. (2009) EMAP II Is a Novel Cigarette Smoke-Induced Biomarker in Emphysema. (May)
  • Sethi S;Berenson CS, Clare RL, Maloney J,. (2009) Distinct Innate Immune Responses of COPD Alveolar Macrophages to Different Respiratory Bacterial Pathogens. Oral presentation, Mini-Symposium, Innate lung defense in chronic obstructive pulmonary disease. (May)
  • Sethi S;Rupp A, Romberger DJ, Tang L,T.D. LeVan. (2009) Differential Susceptibility of Nontypeable Haemophilus influenzae Strains to the Antimicrobial Peptide, Human ß-Defensin-2, in COPD Subjects. (May)
  • Sethi S;Siddiqi A, Berim I, Nabi H, Berenson CS. (2009) Association of Impaired Mucociliary Clearance with Occurrence of Exacerbations in COPD. Oral presentation, Mini-Symposium, Chronic obstructive pulmonary. (May)
  • Sethi S, Parameswaran, G.I., Murphy TF. (2009) Antimicrobial Polypeptides and Moraxella Catarrhalis in COPD. (May)
  • Sethi S;Wrona C, Grove L, Palaniyar N,CS Berenson. (2009) Antimicrobial Polypeptides in Bronchial Lavage and Bronchoalveolar Lavage: Effects of COPD and Current Smoking. Oral presentation, Mini-Symposium, Innate lung defense in chronic obstructive pulmonary disease. (May)
  • Sethi S;Parameswaran GI,TF Murphy. (2009) Protease-Antiprotease Balance Is Altered in Colonization and Exacerbation Due to Moraxella Catarrhalis in COPD. (May)
  • Sethi S;Wilcox T, Leidy NK, PW Jones. (2009) Patterns of Recovery from Exacerbations of COPD: EXACT Change Scores Days 1–14. Oral presentation, Mini-Symposium, Chronic obstructive pulmonary disease exacerbation: mechanism and management. (May)
  • Sethi S;El-Dika N, Wrona C, Eschberger K and TF Murphy. (2009) Molecular Methods Detect Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis in Sputum in COPD with Much Higher Frequency Than Culture Methods. (May)
  • Sethi S;Jung J, Thomas MK, Sethi R ,Tewke CD, Murphy TF. (2009) New Strain Acquisition of Klebsiella Spp, Enterobacter Spp and Escherichia coli in COPD Is Not Associated with Exacerbations. (May)
  • Sethi S;Leidy NK, Wilcox TK,P.W. Jones. (2009) How Stable Is Stable in COPD? An Analysis of Day-to-Day EXACT Score Variability in Acute and Stable Patients with COPD. (May)
  • Sethi S;Lucht LA, Kristoff J, Norris KA,Sciurba FC, Wei K, Tseng W, A. Morris. (2008) Pneumocystis Antibody Response and Colonization in COPD. (May)
  • Sethi S and the PULSE study group. (2008) Reduction in Number of Acute Exacerbations of COPD with Moxifloxacin in Patients with Mucopurulent/Purulent Sputum: A PULSE Study Sub-Analysis. Oral presentation. (May)
  • Sethi S;Leidy NK, Wilcox TK, Burke LB, Howard KA, Petrillo JM, Jones PW,Powers JH. (2008) Reliability and Validity of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT): A New Outcome Measure for Evaluating Exacerbations in COPD. (May)
  • Sethi S; Siddiqi A, Wrona C, Eschberger K, Murphy TF,. (2008) Serum C-Reactive Protein (CRP) in COPD and Its Relationship to Inhaled and Systemic Corticosteroid Use. (May)
  • Sethi S;Wrona C, Eschberger K, Lobbins P, TF Murphy. (2008) Airway Inflammation and Acquisition of New Strains of Moraxella catarrhalis in COPD. (May)
  • Sethi S;Siddiqi A, Grove L, Lobbins P, Eschberger K, Murphy TF,. (2008) Comparison of Antibiotic Susceptibility of Pseudomonas aeruginosa Strains Isolated from Sputum in COPD with Nosocomial Strains. (May)
  • Sethi S;Richardson SK, Manzel LJ, Murphy TF, St. Geme III JW, DC Look. (2008) Cigarette Smoke Extract Alters Bacterial Adherence of Nontypeable Haemophilus influenzae to Airway Epithelial Cells. (May)
  • Sethi S;Wilcox TK, Leidy NK, Chen WH,Jones PW. (2008) Does a Measurement Tool of COPD Exacerbation Have a Single Measurement Scale with Multiple Domains? Exploratory and Confirmatory Factor Analysis of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT). (May)
  • Sethi S and the PULSE study group. (2008) Determinants of Exacerbation Frequency in the PULSE Study. (May)
  • Sethi S;Wrona C, Grove L, Maloney J, C. Berenson. (2008) Bronchial Lysozyme, Lactoferrin and SLPI Concentrations in Ex-Smokers with and without COPD. (May)
  • Sethi S;Wrona C, Grove L, Maloney J, Berenson C, N. Palaniyar. (2008) Bronchoalveolar Lavage Levels of Surfactant Protein A and D Levels Are Decreased in Ex-Smokers with COPD. (May)
  • Sethi S;Jones PW, Chen WH, Leidy NK, Petrillo JM,. (2008) Creating a Unidimensional Measure of Overall Exacerbation Severity: The Exacerbations of Chronic Pulmonary Disease Tool (EXACT). (May)
  • Sethi S. (2008) Development of a Patient-Reported Outcome (PRO) Measure in AECOPD. (May)
  • Sethi S;Kruesmann F, Haverstock D, Perroncel R, Choudhri SH. (2007) Correlation between eradication of infecting organism on days 3 to 5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB). (Sep)
  • Sethi S. (2007) Clinical and safety results of the PULSE Study. Oral presentation. (Sep)
  • Sethi S;Van Parijs BA,Lode H, Wilson R, Bhatt K, Fernandes A, Berkowitz E, Chang C, Nicholson T, Li G, Jones PW. (2007) Patient-Reported Outcome (PRO) Measure in AECOPD. (Sep)
  • Sethi S;Gaillat J, Garau J,Anzueto A, Guillemot D, Weber P. (2007) Impact of telithromycin, azithromycin and cefuroxime axetil on the carriage of resistant Streptococcus pneumoniae in patients with acute exacerbation of chronic bronchitis. (Sep)
  • Sethi S;Wrona C, Murphy TF. (2007) Identification of Nontypeable Haemophilus influenzae (NTHI) Antigens for Human Bactericidal Antibodies That Develop Following Acute Exacerbations of COPD. (May)
  • Sethi S. (2007) Intermittent Pulse Therapy of Moxifloxacin To Prevent Acute Exacerbations in COPD Patients with Chronic Bronchitis: Demographics and Baseline Bacteriology. (May)
  • Sethi S;El-Dika N, T.F. Murphy TF, Wrona C, Eschberger K,. (2007) PCR Detection of Streptococcus pneumoniae and Moraxella catarrhalis in Sputum in the Stable Phase and during Exacerbations of COPD. (May)
  • Sethi S;Veeramachaneni S, Murphy TF, Wrona C, Eschberger K. (2007) Serum IgG and Sputum IgA Antibody Levels to Nontypeable Haemophilus influenzae Are Markers of Recurrent Infection in COPD. (May)
  • Sethi S;Leidy NK, Howard K, Petrillo J, Wilcox T,Jones PW,. (2007) EXACT-PRO Study Group. The EXAcerbation of Chronic Pulmonary Disease Tool [EXACT]: A Patient-Reported Outcome. (May)
  • Sethi S;Wrona C, Cai X,Eschberger K, Murphy TF. (2007) Stability of Serum C-Reactive Protein (CRP) in COPD and Its Relationship to Exacerbation Frequency and Mortality. (May)
  • Sethi S;Clare RL, Grove L, Maloney J, Berenson CS. (2007) Complement Mediation of Human Alveolar Macrophage Phagocytosis Is Distinct for Different Respiratory Pathogens. (May)
  • Sethi S;Richardson SK, Cholon DM, Chin CL, Murphy TF, Sethi S, St. Geme III JW, Look DC. (2007) Altered Adhesin Expression on Persistent Haemophilus influenzae Strains from Patients with Chronic Obstructive Pulmonary Disease. (May)
  • Sethi S. (2007) An epidemiological analysis of Streptococcus pneumoniae infection in outpatient acute exacerbations of chronic bronchitis (AECB). (Apr)
  • Sethi S;Murphy TF, Cai X, Richter SS, Doern GV. (2006) Antibiotic exposure in COPD and the development of penicillin and erythromycin resistance in Streptococcus pneumonia. (Sep)
  • Sethi S;Anzueto A, Wilson R, Jones PW, Wedzicha JA, Miravitlles M, Kureshi A, Sagnier P, Russell J, Schmitt M, Arvis P, Hampel B. (2006) Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data. (Sep)
  • Sethi S;Grove L, Wrona C, Maloney J. (2006) Prevalence of bacterial colonization in COPD is not altered by fluticasone/salmeterol. (May)
  • Sethi S;ElDika N, Eschberger K, Lobbins P, Murphy TF,. (2006) Relationship of Pseudomonas aeruginosa isolation to lung function, hospitalization and mortality in COPD. (May)
  • Sethi S;Veeramachaneni S, Wrona C, Murphy TF,. (2006) Lack of host immune and inflammatory response to gram-negative bacilli in exacerbations of COPD. (May)
  • Sethi S;Brauer AL, Lesse AJ,Kilian M, Cai X, Murphy TF. (2006) Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. (Abstract). (May)
  • Sethi S;Wei KK,Tseng W, Morris A. (2006) Detection of Pneumocystis in subjects with COPD exacerbations. (May)
  • Sethi S;Wrona C, Veeramachaneni S, Eschberger K, Murphy TF. (2006) Changes in serum c-reactive protein (CRP) with onset and resolution of exacerbations of COPD and relationship to etiology. (May)
  • Sethi S;Johnson A, Kazani S, Hiltke TJ,. Musher DM, Ceasar H, Hollingshead SK, Coan PA, Briles DE, Morona J, Paton JC,Murphy TF. (2005) Antibody Response to Capsular and Noncapsular Antigens of Streptococcus pneumoniae in Chronic Obstructive Pulmonary Disease. (Jun)
  • Sethi S;. (2005) Identification of Surface Antigens of Moraxella catarrhalis as Targets of Human Serum Antibody Responses in Chronic Obstructive Pulmonary Disease. (Jun)
  • Sethi S;Fernaays MM, Lesse AJ, Murphy TF. (2005) Genes Associated with Virulence of Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. (Jun)
  • Sethi S;Maloney J, Grove L, Wrona C, Berenson C. (2005) Inflammatory Cytokine Response of Alveolar Macrophages to Outer Membrane Components of Nontypeable Haemophilus influenzae (NTHI) Is Diminished in COPD. (May)
  • Sethi S;Morris A, Sciurba FC, Tseng W, Norris KA,. (2005) Relationship of Pneumocystis Colonization and COPD. (May)
  • Sethi S;Garlipp MA, Maloney J, Berenson C. (2005) Phagocytosis of Nontypeable Haemophilus influenzae (NTHI) by Alveolar Macrophages Is Diminished in COPD. (May)
  • Sethi S;Brown S, Patel M. (2005) Antibacterial Activity of Telithromycin and Comparators Against Pathogens Isolated from Patients with Acute Exacerbations of Chronic Bronchitis in PROTEKT (1999–2003). (May)
  • Sethi S;Wrona C, Maloney J, Berenson C. (2005) Bacterial Colonization Is Associated with Increased Matrix Metalloproteinase-9 (MMP-9) in Bronchoalveolar Lavage of Ex-Smokers with Stable COPD. (May)
  • Sethi S;Delgado EM, Eschberger K, Lobbins P, Murphy TF. (2005) Acquisition of New Bacterial Strains in COPD Is Independent of Systemic Antibiotic and Corticosteroid Use. (May)
  • Sethi S;Wrona C Eschberger K, Lobbins P, Murphy TF. (2005) Changes in Airway Inflammation with Onset and Resolution of Exacerbations of COPD. (May)
  • Sethi S;Brauer A Lesse AJ, Doern GV, Murphy TF. (2005) Distinct Clinical Characteristics of Variant Strains of Nontypeable Haemophilus influenzae (NTHI) Isolated from Patients with COPD. (May)
  • Sethi S;Eschberger K, Lobbins P, Sethi R, Agarwal S, Grant BJB, Murphy TF. (2005) Sputum Bacterial Titers and Acute Exacerbations of COPD. (May)
  • Sethi S;Brauer A, Lobbins P, Eschberger K, Murpy TF. (2004) Systemic and mucosal immune response to Moraxella catarrhalis in COPD. (May)
  • Sethi S;Grove L, Murphy TF,. (2004) Epithelial cell invasion and phosphorylcholine expression among complement sensitive and resistant strains of Haemophilus influenzae isolated from patients with exacerbations of COPD. (May)
  • Sethi S;Maloney J, Grove L, Wrona C, Berenson CS. (2004) Bacterial ‘Colonization’ of the Lower Respiratory Tract Is Associated with Airway Inflammation in Ex-Smokers with Stable COPD. (May)
  • Sethi S;Garlipp M, Sethi S, Grove L, Maloney J, Berenson C. (2004) Phagocytosis and intracellular survival of Nontypeable Haemophilus influenzae in human alveolar macrophages in chronic obstructive pulmonary disease. (May)
  • Sethi S. (2004) Serum immune response to ‘colonization’ by Haemophilus influenzae in COPD. (May)
  • Sethi S. (2004) Serum immune response to ‘colonization’ by Haemophilus influenzae in COPD. (May)
  • Sethi S;Johnson AJ, Kazani S, Hiltke T, Sethi S, Ceaser H, Musher D, Murphy TF. (2004) Human antibody response to Streptococcus pneumoniae in chronic obstructive pulmonary disease. (May)
  • Sethi S;Berenson C, Wrona C, Grove L, Maloney J. (2004) Nontypeable Haemophilus influenzae antigen regulation of human macrophage inflammation. (May)
  • Sethi S;Berenson C, Smigiera J, Grove L, Wrona C,. (2003) Nontypeable Haemophilus influenzae antigen regulation of human macrophage inflammation. (May)
  • Sethi S;Brauer AL, Sethi S, Murphy TF. (2003) New serum IgG and sputum IgA to Moraxella catarrhalis following exacerbations and asymptomatic colonization of adults with chronic obstructive pulmonary disease. (May)
  • Sethi S;Veeramachaneni S, Murphy TF. (2003) Serum immune response to Pseudomonas aeruginosa, other gram-negative bacilli and Haemophilus parainfluenzae in acute exacerbations of COPD. (May) 221
  • Sethi S;, Maloney J, Grove L, Wrona C, Hawkins S. (2003) Safety and efficacy of sputum induction with the lung flute in healthy subjects. (May) D81
  • Sethi S;Wrona C, Braciak C, Freeburg R, Evans N, Murphy TF. (2003) Strain specific immune response to Haemophilus influenzae in exacerbations of COPD. (May)
  • Sethi S;Maloney J, Grove L, Smigiera J, Berenson C. (2003) Colonization’ of the lower respiratory tract and airway neutrophilia in ex-smokers with stable COPD. (May) H63
  • Sethi S. (2003) Strain specific immune response to Haemophilus influenzae in exacerbations of COPD. (May)
  • Sethi S;Maloney J, Grove L, Wrona C, Hawkins S. (2003) Comparison of the safety and efficacy of sputum induction with the lung flute and with hypertonic saline in COPD. (May) D82
  • Sethi S;Brauer AL, Murphy TF. (2002) Strain specificity and duration of human immune response to Moraxella catarrhalis. (May)
  • Sethi S;Evans N, Murphy TF. (2002) Acquisition of a new bacterial strain and occurrence of exacerbation of COPD. (May) A269
  • Sethi S;Ahn JH, Wrona C,. (2002) Exacerbation and transient colonization strains of nontypeable Haemophilus influenzae differ in invasion and pro-inflammatory cytokine induction of H292 cells. (May) A57
  • Sethi S;Obaji A, Murphy TF,. (2002) Relationship of sputum elastase to clinical and bacteriological states in COPD. (May) A326
  • Sethi S;Hiltke TJ, Schiffmacher AT, Murphy TF. (2002) Horizontal transfer of the gene encoding outer membrane protein 2 in a patient with chronic obstructive pulmonary disease. (May)
  • Sethi S;Evans N, Wrona C, Walters A, Murphy TF. (2001) Human immune response to ‘colonization’ by Haemophilus influenzae in stable COPD. (May) J125
  • Sethi S;Veeramachaneni S, Evans N, Wrona C, Walters A, Murphy TF. (2001) Human immune response to Haemophilus spp. in acute exacerbations of COPD. (May) 331
  • Sethi S;Bakri FG, Murphy TF. (2001) Human immune response to Moraxella catarrhalis following exacerbations of chronic obstructive pulmonary disease. (May) 330
  • Sethi S;Obaji A, Murphy TF. (2001) Lung function decline in advanced COPD. (May) K9
  • Sethi S;Hiltke TJ, Murphy TF. (2001) Sequence stability of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae in the human respiratory tract. (May) 96
  • Sethi S;Walters A, Veeramachaneni S, Murphy TF. (2001) Characterization of bactericidal antibodies to tbp2 (OMP B1) of M. catarrhalis. (May) 125
  • Sethi S;Wrona C, Murphy TF. (2000) Characterization of adherence of Moraxella catarrhalis to Hep-2 cells. (May) 68
  • Sethi S;Evans N, Wrona C, Murphy TF. (2000) Airway inflammation in COPD: effects of clinical status and bacterial infection. (May) C25
  • Sethi S;Veeramachaneni S, Evans N, Wrona C, Grant BJB. (2000) Airway inflammation in stable COPD: effect of bacterial colonization is independent of smoking and severity of airway obstruction. (May) C26
  • Sethi S;Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF. (1999) Comparison of airway inflammation in acute bacterial and non-bacterial exacerbations of COPD. (May) 158
  • Sethi S;Yuskiw N, Klingman KL, Brueggemann AB, Doern GV, Murphy TF. (1999) Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. (May) 12
  • Sethi S;Paluri R, Murphy TF. (1999) Sputum bacterial titers do not increase during acute exacerbations of chronic obstructive pulmonary disease (COPD). (May) 264
  • Sethi S;Paluri R, Grant BJB, Murphy TF. (1999) Prediction models for the etiology of acute exacerbations of COPD. (Apr) A141
  • Sethi S;Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF. (1999) Bacterial colonization enhances airway inflammation. (Apr) A142
  • Sethi S;Wrona CT, Klingman KL, Murphy TF. (1998) Serum opsonic antibody response to Moraxella (Branhamella) catarrhalis in acute exacerbations of chronic obstructive pulmonary disease (COPD). (May) 115
  • Sethi S;Ameen KA, Murphy TF. (1998) Mapping of monoclonal antibodies 1F5 and 2.9F to the first variable region of CopB (OMP B2) of Moraxella (Branhamella) catarrhalis. (May) 115
  • Sethi S;Pingle D, Klingman KL, Murphy TF. (1998) Detection of Haemophilus DNA from culture negative sputa in COPD. (Apr) E22
  • Sethi S;Kirkham C, Murphy TF. (1997) Human immune response to outer membrane protein E of Branhamella catarrhalis. (May) 30
  • Sethi S;Ameen K, Murphy TF, Klingman KL,. (1997) Immune response to M. catarrhalis in COPD exacerbations. (May) G32
  • Sethi S;Muscarella KA, Murphy TF. (1997) Serum bactericidal activity for nontypeable Haemophilus influenzae (NTHI): the third factor phenomenon. (May) 245
  • Sethi S;Murphy E, Muscarella KA, Murphy TF. (1996) Dynamics of respiratory tract colonization by nontypeable Haemophilus influenzae in patients with COPD. (May) 185
  • Sethi S;Klingman K, Evans N, Muscarella K, Murphy TF. (1996) Exacerbations of COPD are associated with acquisition of new strains of bacterial pathogens. (May) A825
  • Sethi S;Murphy TF. (1995) Molecular analysis of the outer membrane protein (OMP) B2 gene of Moraxella (Branhamella) catarrhalis. (May) 192
  • Sethi S;Evans N, Muscarella K, Klingman K, Murphy TF. (1995) Sputum induction in stable chronic obstructive pulmonary disease (COPD): effect on sputum bacteriology. (May) A839
  • Sethi S;Murphy TF, Hill SL. (1994) Serum antibody response to Moraxella catarrhalis in bronchiectasis. (May) A121
  • Sethi S;Surface JM, Sethi S, DeNardin E, Murphy TF. (1994) Antigenic heterogeneity of outer membrane protein B of Moraxella (Branhamella) catarrhalis. (May) 135
See all (149 more)

Professional Memberships:

  • ACP; Fellow (2009–present)
  • American Thoracic Society (1990–present)

Presentations:

  • "Changing Paradigms in the Prevention of COPD Exacerbations." Grand Rounds, Quinnipiac Frank H. Netter School of Medicine; Quinnipiac University (2017)
  • "COPD Phenotypes, Outside Looking In" Yale State Chest Conference; Yale School of Medicine (2017)
  • "Lung Microbiome in COPD: Progress and Pitfalls" Yale School of Medicine Research Conference; Yale School of Medicine; Pulmonary Division (2017)
  • "How Should I Treat a Patient Who Has an Acute Worsening in Symptoms?" ATS International Conference; American Thoracic Society; Post Graduate Course PG19 (2016)
  • "Bacterial Infection in COPD: Consequences and Mechanisms" Irish Thoracic Society Annual Meeting (2015)
  • "Severe Infections in COPD. Session 5: Severe infections in COPD and cystic fibrosis." LUSEP: The first Lund conference on severe infections and sepsis. (2015)
  • "Microbiology in Bronchiectasis: Emerging Tools to Identify Pathogens. The frontiers of bronchiectasis." ATS International Conference; ATS (2015)
  • "The Frequent Exacerbator: Determining the Biological Basis. Preventing COPD exacerbations: moving towards targeted and personalized treatment." ATS International Conference; ATS (2015)
  • "The Microbiome in COPD." ATS International Conference; ATS (2015)
  • "The role of the lung microbiome in COPD pathogenesis." Heart & Lung Scientific Symposium; University of British Columbia; Graeme Copland Memorial Lecture (2015)
  • "COPD Exacerbations: An Update." Chest 2014; Chest; Panel Discussion (2014)
  • "Host defense: ABCD." PULMOCON; ; Symposium: Lung Infections: Review of the basic issues. (2014)
  • "Infection in the pathogenesis of COPD." PULMOCON (2014)
  • "LRTI: COPD exacerbation" PULMOCON (2014)
  • "Reducing Relapse Rates for Cigarette Smoking and AECOPD" Chest 2014; Chest; Small Case-Based Interactive Discussion. (2014)
  • "Strategies to Reduce Readmissions for COPD." Chest 2014; Chest; Morning Educational Symposium: AECOPD: Strategies to Improve Outcomes and Reduce Readmission Rates. (2014)
  • "Treatment of infection in COPD exacerbations" European Respiratory Society Annual Congress; ; Postgraduate Course: Lower respiratory tract infections: learning from real clinical cases (2014)
  • "Infection in exacerbations of COPD: More than meets the eye." 28th Annual Doctor Dorothy Wiselberg Seminar, McGill University Health Centre Division of Respiratory Medicine; ; Emerging Respiratory Infections (2014)
  • "Macrolides to Prevent Exacerbations in Chronic Obstructive Pulmonary Disease: Ready for Prime Time?" ATS International Conference; ATS; Symposium: Macrolides in respiratory infections: panacea or pandora's box? (2014)
  • "New Concepts in COPD Exacerbations" ATS International Conference; ATS; Postgraduate Course: COPD: Progress and Controversies (2014)
  • "Preventing COPD exacerbations: Why and How?" International Conference on Insights and Management of COPD (ICONIC) (2014)
  • "Selecting an antibiotic: an art and the science." PULMOCON; ; Symposium: International symposium on LRTI (2014)
  • "Haemophilus influenzae in COPD" Pittsburgh Lung Conference (2013)
  • "ICU Management of COPD. Symposium: Pathogenesis & Management of COPD" Second update on Asthma & COPD (2013)
  • "Use of antibiotics in asthma and COPD" Second update on Asthma & COPD; ; Symposium: Asthma and COPD: Similarities and Differences (2013)
  • "Treating Exacerbations-Prednisone, antibiotics, or both? Symposium: Opportunities to Advance the Care of COPD Exacerbations." COPD8 USA Conference; The COPD Foundation (2013)
  • "What Do We Know About Exacerbations? Symposium: The Science of Exacerbations." COPD8 USA Conference; The COPD Foundation (2013)
  • "Chronic obstructive lung disease: can biomarkers discriminate between causes of acute exacerbations and pneumonia." ATS International Conference; ATS; Postgraduate course: Clinical applications of novel diagnostics and biomarkers for management of respiratory and critical illness. (2013)
  • "Current knowledge of bacterial exacerbations. Symposium: Exacerbations of chronic obstructive pulmonary disease: current state of knowledge." ATS International Conference; ATS (2013)
  • "How to deal with the frequent exacerbator? Symposium: Case based learning in Chronic Obstructive Pulmonary Disease management." ATS International Conference; American Thoracic Society (2013)
  • "Long term antibiotic and macrolide therapy in COPD." ATS International Conference; ATS; Postgraduate course: Update in Chronic obstructive pulmonary disease management/ (2013)
  • "ICU management of acute exacerbation of COPD" KEEP Program in Respiratory Diseases, Wave Two; ; COPD, Sleep Apnea and Lung infection (2012)
  • "Management of community acquired pneumonia" KEEP Program in Respiratory diseases, Wave Two; ; COPD, Sleep Apnea and Lung Infection (2012)
  • "Practical consideration in managing lung infection. KEEP Program in Respiratory diseases, Wave Two" KEEP Program in Respiratory diseases, Wave Two; ; COPD, Sleep Apnea and Lung infection (2012)
  • "Ventilator associated pneumonia" KEEP Program in Respiratory diseases, Wave Two; ; COPD, Sleep Apnea and Lung infection (2012)
  • "How can we better prevent exacerbations of COPD? Symposium : Prevention and treatment of infective exacerbations of COPD." European Respiratory Society Annual Congress; European Respiratory Society; Symposium : Prevention and treatment of infective exacerbations of COPD. (2012)
  • "Infection and inflammation in AECOPD: understanding patient phenotypes." European Respiratory Society Annual Congress; European Respiratory Society Annual Congress; Evening Symposium : Prevention of exacerbations in COPD: expanding scope and strategies. (2012)
  • "Altered innate lung defense: the biological basis of exacerbation susceptibility?" ATS International Conference; ATS; ? Postgraduate Course: Exacerbations of chronic obstructive pulmonary disease: measurement, mechanisms, modeling and management. (2012)
  • "Bacterial infection and mucus hypersecretion" ATS International Conference; ATS; Symposium: Mechanisms and implications of mucus accumulation in chronic obstructive pulmonary disease. (2012)
  • "Pharmacological treatment of stable copd: when and with what?" ATS International Conference; ATS; Thematic Seminar Series: Chronic obstructive pulmonary disease. (2012)
  • "Pneumonia: Newer Pathogens, New Resisitance." Internal Medicine 2012 American College of Physicians Annual Conference.; American College of Physicians (2012)
  • "An Exacerbation Free COPD Patient: Is that a Pipe Dream" Yale State Chest Conference; Yale University (2012)
  • "Antibiotic treatment of exacerbations of COPD: when, why and how" European Respiratory Society Annual Congress; European Respiratory Society; Meet the Professor Seminar (2011)
  • "Bacteria in acute exacerbations of COPD: Cause or co-morbidity?" European Respiratory Society Annual Congress; European Respiratory Society; Evening Symposium: New decade, new approaches to respiratory tract infections. (2011)
  • "Chosing the right antimicrobial, route of administration and dosage for chronic bronchial infection." European Respiratory Society Annual Congress; European Respiratory Society; Symposium: Chronic Bacterial infection: more than a syndrome (2011)
  • "Mechanisms of Bacterial Infection in COPD. Mini-symposium: COPD exacerbations: impact of bacterial and viral infections" ATS International Conference; American Thoracic Society (2011)
  • "Controversies in the management of adult respiratory infections: What is the role of combination therapy in severe CAP and VAP?" Lebanese Pulmonary Society Annual Congress,; Lebanese Pulmonary Society (2011)
  • "Prior Antibiotic Use: Why does it Matter in Community Acquired Pneumonia (CAP)?" Lebanese Pulmonary Society Annual Congress; Lebanese Pulmonary Society (2011)
  • "Bacterial Infection in COPD, Consequences and Mechanisms." Pulmonary Grand Rounds; University of Massachusetts (2011)
  • "Treating for better outcomes: the role of moxifloxacin in AECB" Asia Pacific Society of Respirology Annual Congress; Asia Pacific Society of Respirology; Satellite Symposium (2010)
  • "Acute Exacerbations of Chronic Bronchitis (AECB). Who Needs Antibiotics?" European Respiratory Society Annual Congress; European Respiratory Society; Evening symposium (2010)
  • "The Evidence for Long-Term Antimicrobials in Reducing Exacerbations of COPD." European Respiratory Society Annual Congress; European Respiratory Society; evening symposium (2010)
  • "Infection In COPD: Pathogenesis And Treatment." Meet the Professor Seminar, ATS International Conference (2010)
  • "Exacerbations of COPD, More than Chest Colds." Pulmonary Grand Rounds; ; Cedars Sinai Hospital (2010)
  • "Bacterial Infection in COPD, Consequences and Mechanisms." Research Grand Rounds; ; Lovelace Respiratory Research Institute, (2010)
  • "Bacterial Infection in COPD, Consequences and Mechanisms" Pulmonary Grand Rounds; ; University of Iowa (2010)
  • "Exacerbations of COPD. Symposium: Exacerbations of Chronic respiratory Disease: State of the Art" CHEST (2009)
  • "Update in the Current Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD)." Independent Health Foundation (2009)
  • "Exacerbations of COPD: Mechanisms, Management and Prevention." Chicago Thoracic Society (2009)
  • "Etiology of COPD Exacerbations: The Microbiological Link." CHEST; ; Panel Discussion. Revisitng COPD exacerbations. (2008)
  • "Bacterial infection in COPD:" European Respiratory Society Research Seminar: (2008)
  • "Infection And COPD Exacerbation: What Is The Evidence? Symposium: COPD exacerbations: Epidemiology, prevention and treatment." American Thoracic Society International Conference, (2008)
  • "Measuring The “Exacerbation”. Symposium: Measuring outcome in COPD: How do we move the field?" American Thoracic Society International Conference (2008)
  • "Pulmonary Infections In The Immunocompetent Host. Symposium: Clinical year in review 2." American Thoracic Society International Conference (2008)
  • "PULSE: Impact Of Antibiotic Prophylaxis Symposium: Changing the natural history of COPD: Results of major clinical trials." . American Thoracic Society International Conference (2008)
  • "Acute exacerbations of chronic bronchitis (AECB) clinical trial design: relevant end-points. Evening symposium" European Respiratory Society Annual Congress (2007)
  • "Patient’s experience of symptoms during COPD exacerbations. Evening symposium" European Respiratory Society Annual Congress (2007)
  • "Role of Infection in Disease Pathogenesis. Postgraduate Course Session: COPD: State of the art for the clinician and Researcher." American Thoracic Society International Conference (2007)
  • "Causes of Acute Exacerbations. Plenary Session: Exacerbations." Clinical Consensus on COPD (2007)
  • "Patient reported outcomes in AECB. Plenary Session." Fourth Forum on Respiratory Tract Infections (2007)
  • "Taking a closer look at the AECB patient. Evening Symposium: Not all patients are the same – optimizing outcome in respiratory tract infections." European Respiratory Society Annual Congress (2006)
  • "Importance of antimicrobial therapy. Symposium: Exacerbations." COPD 5 (2006)
  • "Adding oil to the fire: systemic and mucosal inflammation in exacerbations. Symposium: Is COPD an inflammatory disease." American Thoracic Society International Conference (2006)
  • "Bacterial microbes and COPD: Cause or effect." American Thoracic Society International Conference; ; Postgraduate Course Session: What’s new in COPD: Fourth leading cause of death in the 21st century. (2006)
  • "Current concepts and future trends in the diagnosis and treatment of RTI’s. Symposium: Advances in respiratory infection treatment." 9th Annual Making a Difference in Infectious Disease (MAD-ID) Pharmacotherapy Conference (2006)
  • "Role of Infection in Disease Pathogenesis" American Thoracic Society International Conference; ; Postgraduate Course Session: COPD: Update for the Clinician and Researcher (2006)
  • "The role of Haemophilus influenzae in COPD. Symposium: Molecular and epidemiologic tools to study respiratory infections: Recent advances, current controversies and future directions" American Thoracic Society International Conference (2006)
  • "COPD: What therapy works?" American College of Physicians Annual Conference (2006)
  • "Mechanisms of colonization and effects of exacerbations. Symposium: COPD progression – from smoking to Chronic Respiratory Failure." 5th International Conference on Management and Rehabilitation of Chronic Respiratory Failure. (2006)
  • "Acute exacerbations of COPD, What is new?" Yale State Chest Conference (2005)
  • "Pathogenesis of acute exacerbations of chronic bronchitis (AECB): What is new?" CHEST (2005)
  • "Role of infection in acute exacerbations of chronic bronchitis (AECB)." CHEST (2005)
  • "A Sterile Airway Is A Happy Airway: Antibiotics. Symposium: Prevention of COPD exacerbation: are we there yet?" American Thoracic Society International Conference (2005)
  • "Airway Infection and COPD Progression. Symposium: New frontiers in the progression of COPD." American Thoracic Society International Conference (2005)
  • "Pathogenesis of and Immune Response to Bacterial Infection in COPD. Symposium: Airway infections: Pathogenesis and consequences." American Thoracic Society International Conference (2005)
  • "Role of Microorganisms in Disease Progression." American Thoracic Society International Conference; ; Postgraduate Course Session: COPD: State of the art for the clinician and Researcher (2005)
  • "New approaches to understanding AECOPD and current therapeutic trends." ECCMID (2005)
  • "Bacteriology of Acute Exacerbations. Panel Discussion: Update in Acute Exacerbations" CHEST (2004)
  • "Bacterial Pathogenesis of AECB – understanding the role of bacteria in AECB" European Respiratory Society Annual Congress (2004)
  • "Bacterial Infection in COPD: Phenomenon or Epiphenomenon" Copeland lecture; St Vincent’s Hospital (2004)
  • "Role of bacteria-colonization versus exacerbations. Plenary session on exacerbations." COPD 4 (2004)
  • "Bacteria - cause or innocent bystander" American Thoracic Society International Conference (2004)
  • "Immune response to bacterial pathogens in COPD" American Thoracic Society International Conference (2004)
  • "Bacterial pathogenesis of AECB." Third Forum on Respiratory Tract Infections (2004)
  • "The role of bacteria in COPD and AECOPD." CHEST International Conference (2003)
  • "Acute exacerbations of COPD: more than “chest colds”" American Thoracic Society International Conference, (2003)
  • "Microbes and exacerbations of COPD, old friends or new enemies?" American Thoracic Society International Conference, (2003)
  • "Bacteria in exacerbations of COPD" Exacerbations in COPD and Asthma: Mechanisms and Medicines Symposium. (2003)
  • "Bacterial Infection in COPD: Phenomenon or Epiphenomenon" New York State Thoracic Society Annual Scientific Assembly (2003)
  • "Bacteriology of acute exacerbations of chronic bronchitis." ATS International Conference (2002)
  • "Ventilator associated pneumonia" Second VA Critical Care Symposium (2002)
  • "Classification and differential diagnosis of acute exacerbations of chronic bronchitis" CHEST International Conference (2001)
  • "Role of viral respiratory infection in AECB, with a focus on Rhinovirus." CHEST International Conference (2001)
  • "Can we reduce the frequency of acute exacerbation of COPD?" Annual Advances in Pulmonary and Critical Care Medicine Symposium. (2001)
  • "New concepts in the pathogenesis of bacterial exacerbation of COPD" Annual Advances in Pulmonary and Critical Care Medicine Symposium. (2001)
  • "Bacterial persistence, eradication and dormancy" Forum on Respiratory Infections (2000)
  • "Ventilator-associated Pneumonia in the new millennium." City Wide Grand Rounds; State University of New York at Buffalo; Department of Medicine (2000)
  • "Bacterial infection in COPD" Aspen Lung Conference (1999)
  • "Acute Bronchitis. Acute exacerbations of chronic bronchitis and community acquired pneumonia - which antibiotic (if any) do we select?" ALA/ATS International Conference (1999)
  • "Airway inflammation in COPD: Role of bacterial infection." ; Department of Medicine, State University of New York at Buffalo; City Wide Grand Rounds (1998)
  • "Role of infections in chronic bronchitis. National satellite video-conference: Challenges in Primary Care: Practical management of Chronic Bronchitis." Annual Scientific Assembly; Southern Medical Association, (1997)
  • "Bacteriologic considerations in patients with COPD. Panel Discussion: How to apply guidelines to antibiotic therapy in COPD patients." CHEST (1997)
  • "Acute bacterial infection in COPD patients: New Insights." Annual Advances in Pulmonary and Critical Care Medicine Symposium (1997)
  • "Parameters of clinical outcomes of AECB" Annual Advances in Pulmonary and Critical Care Medicine Symposium (1997)
  • "Bacterial infection in COPD: what’s new?" Southern California Pulmonary Research Conference. (1997)
See all (105 more)

Service Activities:

  • VA Clinical Services Research and Development Program; Ad Hoc Reviewer (2020)
  • Executive Board, UB Clinical and Translational Science Institute (2020–present)
  • Co-Chair, UB ECMC and Kaleida Clinical Research Governance Committee (2019–present)
  • UB Department of Medicine Compensation Committee (2019–present)
  • Ireland Health Research Board; Ad Hoc Reviewer (2019)
  • NHLBI Clinical Research LRP; Ad Hoc Reviewer (2018–2020)
  • Florida Department of Health; Ad Hoc Reviewer (2018–2020)
  • Ireland Health Research Board; Ad Hoc Reviewer (2017)
  • Austrian Science Fund; Ad Hoc Reviewer (2016)
  • Infection B Study Section, Veterans Affairs Merit Review Program; Ad Hoc Reviewer (2016)
  • Clinical Trial Management System Steering Committee, University at Buffalo (2015–2017)
  • Executive Committee, UB Clinical and Translational Science Institute (2015–present)
  • Veterans Affairs Coordinated Clinical Trials Program; Ad Hoc Reviewer (2015)
  • Florida Department of Health; Ad Hoc Reviewer (2015)
  • Ad hoc committee on promotions to unqualified (tenurial) ranks, University at Buffalo (2014–present)
  • Raine Medical Research Foundation, University of Western Australia; Ad Hoc Reviewer (2013)
  • Research Council of Norway; Ad Hoc Reviewer (2012)
  • Board of Directors, Buffalo Institute of Medical Research (2012–present)
  • Research Council of Norway; Ad Hoc Reviewer (2011–2013)
  • Executive Council, Department of Medicine, University at Buffalo (2011–2015)
  • School of Nursing Dean Search Committee, University at Buffalo (2011)
  • MD/PhD Program Review Committee, University at Buffalo (2011)
  • Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD) Guidelines; Reviewer (2011)
  • American Thoracic Society; Ad Hoc Reviewer (2010)
  • Canadian Cystic Fibrosis Foundation; Ad Hoc Reviewer (2010)
  • Home oxygen committee, VA Hospital (2010–present)
  • Co-chair - Great Lakes Critical Care Committee (2009–2013)
  • ZonMw's Health Care Efficiency Research Programme, Netherlands; Ad Hoc Reviewer (2009)
  • UK Health Protection Agency; Ad Hoc Reviewer (2009)
  • Transverse Research Programs of the Institut Pasteur; Ad Hoc Reviewer (2009)
  • President - Buffalo Institute of Medical Research (2008–2011)
  • Board of Directors - Academic Medicine Services, University at Buffalo (2008–2010)
  • American Thoracic Society; Ad Hoc Reviewer (2008)
  • Pulmonary and Critical Care subcommittee; Co-Chair (2008–present)
  • Chief of Staff search committee; Member (2008–present)
  • Canadian Institutes of Health Research; Ad Hoc Reviewer (2007)
  • Interdisciplinary Research Development Fund (IRDF) Clinical & Behavioral Sciences Panel, University at Buffalo.; Member (2007)
  • UK Medical Research Council;; Ad Hoc Reviewer (2007–present)
  • Department of Veterans Affairs; Veterans Affairs Merit Review Program;; Ad Hoc Reviewer (2007–present)
  • National Heart Lung and Blood Institute;; Ad Hoc Reviewer (2006–present)
  • Dutch Asthma Foundation;; Ad Hoc Reviewer (2006–present)
  • Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD) Guidelines; Reviewer (2005–2006)
  • National Heart Lung and Blood Institute;; Ad Hoc Reviewer (2005–present)
  • Clinical Research Infrastructure committee; Member (2004–2005)
  • European Commission Sixth Framework Programme;; Ad Hoc Reviewer (2004–present)
  • Committee on Promotion to Unqualified (Tenurial) Ranks; Member (2003–2006)
  • Veterans Affairs Merit Review Program, VAMC.; Ad Hoc Reviewer (2003)
  • Human Studies subcommittee (2003–present)
  • Department of Veterans Affairs; Veterans Affairs Merit Review Program;; Ad Hoc Reviewer (2003–present)
  • Member, Program Committee Assembly on Clinical Problems, American Thoracic Society; Committee Member (2002–2011)
  • National Institute of Allergy & Infectious Diseases, National Institute of Health National Institute of Allergy & Infectious Diseases, National Institute of Health; Ad Hoc Reviewer (2002)
  • National Institute of Allergy and Infectious Diseases;; Ad Hoc Reviewer (2002–present)
  • Member, Program Committee Assembly on Microbiology, Tuberculosis & Pulmonary Infections. American Thoracic Society; Member (2002–present)
  • Member, Program Committee Assembly on Clinical Problems; Member (2002–present)
  • Human Studies subcommittee; Chair (2001–2002)
  • Human Studies subcommittee / VA Hospital; Member (2000–present)
  • Mentoring and Evaluation committee; Member (2000–present)
  • Clinical Research committee; Member (2000–present)
  • Research and Development subcommittee / VA Hospital; Member (1996–1999)
  • International Advisory Board/Thorax; Advisory Board
  • Current Respiratory Medicine Reviews; Editorial Board Member
  • Editorial Board/Respiratory Research; Editorial Board Member
  • Epidemiology & Infection; Reviewer
  • European Respiratory Journal; Reviewer
  • Expert Opinion on Emerging Drugs; Reviewer
  • American Journal of Respiratory & Critical Care Medicine; Reviewer
  • American Journal of Respiratory Cell & Molecule Biology; Reviewer
  • American Journal of Respiratory Medicine; Reviewer
  • Canadian Medical Association Journal; Reviewer
  • Chest; Reviewer
  • Clinical Drug Investigation; Reviewer
  • Journal of Antimicrobial Chemotherapy; Reviewer
  • Journal of Investigative Medicine; Reviewer
  • Journal of Respiratory Diseases; Reviewer
  • New England Journal of Medicine; Reviewer
  • Pharmacoeconomics; Reviewer
  • Thorax; Reviewer
  • Pulmonary Pharmacology and Therapeutics; Reviewer
  • Respiration; Reviewer
  • Respiratory Medicine; Reviewer
  • Annals of the American Thoracic Society; Reviewer
  • Antimicrobial Agents and Chemotherapy; Reviewer
  • Antonic van Leeuwenhock; Reviewer
  • Biomarkers; Reviewer
  • BMC Pulmonary Medicine; Reviewer
  • Proceedings of the American Thoracic Society; Reviewer
  • Canadian Respiratory Journal; Reviewer
  • Chemotherapy; Reviewer
  • Clinical Microbiology and Infection; Reviewer
  • COPD: Journal of Chronic Obstructive Pulmonary Disease; Reviewer
  • Critical Care; Reviewer
  • Current Drug Targets; Reviewer
  • Drugs and Aging; Reviewer
  • European Journal of Pharmacology; Reviewer
  • Experimental Lung Research; Reviewer
  • Expert Opinion on Investigational Drugs; Reviewer
  • Expert Review of Molecular Diagnostics; Reviewer
  • Expert Review of Respiratory Medicine; Reviewer
  • FEMS Immunology and Medical Microbiology; Reviewer
  • Human Genetics; Reviewer
  • Infection; Reviewer
  • Infection and Immunity; Reviewer
  • International Journal of Inflammation; Reviewer
  • International Journal of Microbiology; Reviewer
  • International Journal of Clinical Practice; Reviewer
  • International Journal of COPD; Reviewer
  • International Journal of Tuberculosis and Lung Disease; Reviewer
  • JAMA; Reviewer
  • Journal of Antimicrobial Chemotherapy; Reviewer
  • Journal of Clinical Epidemiology; Reviewer
  • Journal of COPD; Reviewer
  • Journal of Cystic Fibrosis; Reviewer
  • Journal of General Internal Medicine; Reviewer
  • Journal of Infectious Diseases; Reviewer
  • Journal of Medical Microbiology; Reviewer
  • Journal of Medical Virology; Reviewer
  • Journal of Respiratory Diseases; Reviewer
  • Lancet; Reviewer
  • Lung; Reviewer
  • Lung; Reviewer
  • Lung India; Reviewer
  • Nicotine and Tabacco Research; Reviewer
  • Pediatric Infectious Disease Journal; Reviewer
  • PLosOne; Reviewer
  • Proceedings of the American Thoracic Society; Reviewer
  • Respiratory Research; Reviewer
  • Scientific Reports; Reviewer
  • Therapeutic Advances in Respiratory Disease; Reviewer

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

Clinical and Translational Research Center
875 Ellicott St.
Room 6045A
Buffalo, New York 14215
Phone: 7168884864
ssethi@buffalo.edu

This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.

View this physician on UBMD